Amgen announces Sjogren's trial results: Amgen stock gains 1.59 percent

Published on 10/07/2026 at 15:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 10.05 billion in the second quarter of 2026, up 9.50 percent year over year. Amgen stock costs EUR 360.18 on October 7, 2026 versus EUR 354.53.

Schwarzweiß-Reportagefoto einer Wissenschaftlerin, die mit Pipette und Zellkultur-Proben im Labor arbeitet — Amgen Inc. (ISIN US0311621009) inspirierte diese dokumentarische Schwarzweiß-Aufnahme einer Forscherin im Biotech-Labor, Illustration mit AI erstellt.

Amgen Inc. (ISIN US0311621009) was trading at EUR 360.18 at Lang & Schwarz on October 7, 2026 at 3:02 p.m. CEST, plus 1.59 percent versus the prior close of EUR 354.53. According to Amgen on September 22, 2026, the biotechnology company announced positive topline phase 3 results for dazodalibep in moderate-to-severe systemic Sjogren's disease.

Sjogren's trial reaches a key test

Amgen said the OASIZ 301 study met its primary endpoint, with improvement in systemic disease activity measured at Week 48. The result gives the company a fresh late-stage pipeline marker while the broader investment case still depends on converting clinical progress into approvals and sales.

The trial update came after Amgen's second-quarter results, which remain the latest reported financial period. Trefis reported that total revenue reached USD 10.05 billion in the second quarter of 2026, up 9.50 percent from the prior-year quarter, while adjusted earnings per share reached USD 6.29 against consensus of USD 5.60.

Guidance sets the financial frame

For fiscal year 2026, Amgen guides to revenue of USD 38.20 billion to USD 39.40 billion and adjusted earnings per share of USD 22.30 to USD 23.50, according to Trefis. The revenue range was raised from prior guidance of USD 37.80 billion, making the outlook a quantified comparison rather than a purely narrative pipeline story.

Amgen's second-quarter 2026 revenue growth also exceeded the consensus estimate of USD 9.43 billion, according to Investing.com. Cantor Fitzgerald reiterated a Neutral rating on October 5, 2026, with a USD 400.00 price target, while the same report cited positive Sjogren's data and a less active catalyst calendar through year-end.

Amgen stock trades above analyst target

For context, the Nasdaq-listed company had a USD 217.0 billion market capitalization on October 6, 2026, according to Trefis. MarketBeat reported a 52-week Nasdaq range of USD 288.00 to USD 447.03, placing the latest primary-market context below the yearly high and above the yearly low.

Trefis lists November 3, 2026, as the next earnings release date. That calendar point should put the second-quarter revenue trajectory, the raised fiscal-year range and the clinical pipeline on the same investor timetable.

Trading signal stays positive

At Lang & Schwarz, Amgen stock was trading at EUR 360.18 on October 7, 2026 at 3:02 p.m. CEST, up 1.59 percent against the EUR 354.53 prior close at Lang & Schwarz. The Nasdaq context was USD 402.60 at the latest finance quote timestamp on October 6, 2026, with a USD 288.00 to USD 447.03 52-week range.

The further course of trading is shown by the continuously updated real-time quote of Amgen stock.